Decision Systems for Medical Device & Pharmaceutical Quality
ParanoiaIQ™ is the decision layer your QMS is missing, a system that ensures decisions are made early, consistently, and defensibly, before they become patient safety incidents or regulatory events.
"Most organizations don't miss risk because they lack data. They miss it because no system forces the right decision at the right time."
A Safe Outcomes LLC product
For device companies: the risk file hasn't kept up with how the product is actually used, manufactured, and failing in the field. For pharmaceutical manufacturers: the deviation system, the CAPA, and the batch record review are all reactive by design.
Signals exist in complaints, deviations, and supplier issues, but they are fragmented, inconsistently evaluated, and often escalated too late. By the time the pattern is clear, the decision is no longer optional. It is already visible to FDA.
Most companies discover their decision gaps during an inspection or a recall. By then, it is too late to fix the system.
The cost is not just recall. It is delayed detection, expanded scope, and loss of control once regulators are involved.
Source: Mooghali M et al., "Characterization of FDA Class I Recalls," Medical Devices: Evidence and Research, 2023. PMID 37229515. n=189 Class I recalls, 2018–2022.
Representative of industry trends. Not product-specific risk.
These are not failures of detection. They are failures of decision timing.
Without ParanoiaIQ™
ParanoiaIQ™
ParanoiaIQ™ reduces regulatory risk by enforcing consistent, auditable decision-making before issues escalate.
This is not about better documentation. It is about controlling outcomes before they escalate.
Every recall traces back to one of three failures.
A single undifferentiated FMEA often misses the problem. Three targeted analyses catch each failure pathway.
Decision criteria are configurable to your product, risk tolerance, and regulatory strategy.
Built to FDA's AI Standard
In April 2026, FDA issued its first Warning Letter citing AI overreliance in manufacturing — requiring that AI outputs be "reviewed and cleared by an authorized human representative." ParanoiaIQ™ satisfies this requirement by design. The Human Gate is not optional. Every recommendation is documented, timestamped, and signed off before any action is taken.
Ref: FDA Warning Letter 320-26-58, Purolea Cosmetics Lab, April 2, 2026 · 21 CFR 211.22(c)
A CAPA is how FDA measures whether you take problems seriously. It is triggered by complaints, deviations, design failures, field actions, and 483 observations. It is the mechanism that connects a quality event to a root cause to a permanent fix.
When CAPAs fail, it is not because the solution was wrong. It is because the problem was never precisely defined.
Problem in Focus: Core Methodology
"The problem must be precisely, specifically, and completely defined before any corrective action is scoped. A vague problem statement produces a vague CAPA that fails FDA scrutiny."
01 · Precision Definition
Problem statements are scored before RCA begins. Vague problems (wrong object, wrong defect, no data anchor) are flagged and returned. You cannot close what you cannot define.
02 · Right-Sized Routing
Not every deviation needs a full CAPA. ParanoiaIQ™ routes events by risk level. Fast-Track correction for known, low-risk issues; full CAPA for systemic failures. No backlog. No overload.
03 · Effectiveness by Design
Effectiveness criteria are defined at CAPA opening, not at closure. Auditors expect criteria established before the fix, not retrofitted after. Reviewers walk out with the standard already documented.
The scenario below shows the full ecosystem: one quality event, both engines running simultaneously, closing through a single Human Gate.
Based on a real Class I recall. Medline Industries, March 2026. Namic angiographic rotating adaptor syringe. Four serious injuries before recall initiation.
The Event
No system replacement. This runs on top of your existing QMS.A field complaint arrives: a rotating adaptor on a contrast media delivery syringe loosened during an interventional cardiology procedure. The scrub tech caught it before full disconnection. No patient harm this time. The complaint is logged in the eQMS.
The complaint is logged in the eQMS and enters the system. ParanoiaIQ™ immediately cross-references it against the device risk file. Adaptor loosening under torsional load is documented in the FMEA — residual risk rated Acceptable. No patient harm on this event. But the complaint rate has now reached 2 in 90 days across 4,200 distributed units. The FMEA probability rating is Rare: fewer than 1 in 10,000 units. The field rate does not match.
Field rate exceeds documented FMEA parameters. CAPA Gate evaluation begins.
Three triggers are evaluated. Severity: no confirmed patient harm on this event — not triggered. Management: no regulatory flag or strategic context requiring escalation — not triggered. Frequency: complaint rate now exceeds the documented FMEA threshold across distributed units. Trigger fires.
Frequency trigger fires. CAPA opened. Problem in Focus begins.
Problem in Focus is applied before any investigation begins. The problem is scoped precisely: rotating adaptor connection loosening under torsional load during high-pressure injection in cardiac catheterization procedures, at a field complaint rate exceeding the documented FMEA probability threshold across affected lot numbers. Not "syringe failure." Not "loose adaptor." Specific object, specific defect, specific conditions, anchored to data.
Root cause scope is set. Investigation method assigned. Effectiveness criteria defined at opening: complaint rate returning below the FMEA-documented threshold within 90 days of corrective action.
During risk assessment inside the CAPA: does this failure affect device function? The syringe delivers contrast media during cardiac catheterization under high injection pressure. A loose connection under load creates a potential pathway to line disconnection mid-procedure. Patient safety exposure identified.
CAPA risk assessment triggers safety escalation. HHE Engine activated.
Probability: Occasional — the complaint rate now exceeds the FMEA documented threshold. Severity: Catastrophic — air embolism or blood loss during an interventional cardiac procedure, high-acuity population, no immediate alternative device. The Probability Override Rule applies: life-sustaining device context with a clear pathway to serious injury or death.
Risk level: High. Class I determination.
Life-sustaining device confirmed. All distributed units carry the potential failure mode. The failure pathway reaches serious injury or death. A market withdrawal or correction is insufficient — the risk profile requires a full recall.
Recommendation: Urgent voluntary recall. Scope: all affected lot numbers.
Both outputs land in one review session. The CAPA packet: problem statement, RCA scope, effectiveness criteria. The field action packet: HHE assessment, MDR determination, recall recommendation — each with full rationale and regulatory citations. The quality professional reviews both, confirms scope, and approves. Decision documented, timestamped, and audit-ready before the next morning.
Time from complaint to decision: 4 hours. One event. Two engines. One documented, auditable decision packet.
What Actually Happened
Medline received complaints over time. The rotating adaptor failure resulted in four serious injuries before the recall was initiated in March 2026. The pattern was in the data. The decision came late.
With ParanoiaIQ™
The rate trigger fires on complaint two. The escalation is automatic and consistent. The HHE and field action recommendation are drafted before the third complaint arrives. Four injuries could have been prevented.
The pattern was already there. The question is whether your system sees it in time.
I built ParanoiaIQ™ because I kept seeing the same failure modes: risk files that had not been updated, CAPAs that closed without fixing the root cause, and escalation decisions that varied by reviewer.
After 25 years inside these decisions at Abbott, Fresenius Medical Care, Integra LifeSciences, NuVasive, and Exactech, I knew the pattern well enough to build a system around it.
Regulatory Situations Navigated
Walk your last quality event through the engine. We will show you exactly where the decision would have changed.
Find the Decision Gaps in Your System20-minute walkthrough. No integration required. Bring a real complaint, deviation, CAPA, or 483 observation — we run it live.